Sitemap| Cellceutix Files Patent Application For Its Cancer Compound |
|
BEVERLY, Mass.--(BUSINESS WIRE)--Cellceutix Corporation (OTCBB: CTIX), today announced it has filed a U.S. patent application covering pharmaceutical formulations of a compound referred to as Kevetrin� and many novel compounds having similar structures to Kevetrin. These structures cover a large number of compounds that Cellceutix can look at as possible drug development candidates. The application covers the use of Kevetrin� and the other compounds in various areas, including cancers. Cellceutix plans to file in other countries within a year of the U.S. filing.
This Press Release contains forward-looking statements that are based on our current expectations, beliefs and assumptions about the industry and markets in which Cellceutix Corporation operates. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause Cellceutix�s actual results to be materially different from any future results expressed or implied by these statements. Actual results may differ materially from what is expressed in these statements, and no assurance can be given that Cellceutix can successfully implement its core business strategy and improve future earnings. The factors that may cause Cellceutix�s actual results to differ from its forward-looking statements include: Our current critical need for additional cash to sustain existing operations and meet ongoing existing obligations and capital requirements; Our ability to implement new product development and commercialization, enter into clinical trials, expand the intellectual property portfolio, and receive regulatory approvals in a timely and cost-effrctive manner. All forward-looking statements are also expressly qualified in their entirety by the cautionary statements included in our SEC filings, including our quarterly reports on Form 1O-Q and annual report on Form 10-K
Leo Ehrlich, Chief Financial Officer 978-633-3623, This e-mail address is being protected from spam bots, you need JavaScript enabled to view it Original article can be viewed here. |